Highlights from

AAN 2019

American Academy of Neurology annual meeting

Philadelphia, USA 4-10 May 2019

Brain-responsive neurostimulation reduces seizures

The complete follow-up of a 7-year prospective open-label long-term treatment study of a responsive neurostimulation system was presented [1]. Patients treated with this type of treatment experienced sustained reductions in seizures. In a third of patients, this reduction was 90% or greater during the last 3 months.

Participants of the long-term treatment study were 230 out of 256 patients who were treated in a 2-year randomised, double-blinded controlled pivotal study (n=191), or a prior 2-year feasibility study (n=65). Mean age was 34 years; mean epilepsy duration 19.6 years; mean number of anti-epileptic drugs used 2.9; median seizure frequency 10.2 per month. The median percent reduction reached 75% at the end of year 9 (n=168). In addition, 30% of subjects experienced at least one seizure-free period of 6 months or more; 19% experienced a seizure-free period of 12 months or more. The median percent reduction in seizures was 67.2%. Infection risk was 3.7% per procedure; all but 1 infection was soft tissue only. There were 16 deaths, 9 due to possible or definite ‘sudden unexpected death in epilepsy’. The authors concluded that these outcomes support the long-term effectiveness and safety of this treatment of medically intractable focal seizures.

  1. Nair D, et al. AAN 2019, S36.005.

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.